A Study of Solifenacin Succinate Compared to Tolterodine in Patients With Overactive Bladder
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00189800 |
Recruitment Status :
Completed
First Posted : September 19, 2005
Last Update Posted : November 17, 2011
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Overactive Bladder | Drug: Solifenacin succinate | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double |
Primary Purpose: | Treatment |


Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Symptoms of overactive bladder
- Must be able to complete the micturition diary
Exclusion Criteria:
- Pregnant or lactating
- Clinically significant outflow obstruction
- Significant post void residual urine
- Significant stress incontinence
- Urinary tract infection
- Chronic inflammation
- Bladder stones
- Previous pelvic radiation therapy
- Previous or current malignant disease of the pelvic organs
- Uncontrolled narrow angle glaucoma
- Urinary or gastric retention
- Electrostimulation therapy
- Bladder training
- Diabetic neuropathy

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00189800
Korea, Republic of | |
Anyang, Korea, Republic of | |
Bucheon, Korea, Republic of | |
Busan, Korea, Republic of | |
Cheonan, Korea, Republic of | |
Daegu, Korea, Republic of | |
Daejeon, Korea, Republic of | |
Gwangju, Korea, Republic of | |
Incheon, Korea, Republic of | |
Seoul, Korea, Republic of | |
Suwon, Korea, Republic of |
Principal Investigator: | Prof. Jeong Gu Lee | Department of Urology, Korea University Anam Hospital |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: | NCT00189800 |
Other Study ID Numbers: |
90502/KOoTD01 |
First Posted: | September 19, 2005 Key Record Dates |
Last Update Posted: | November 17, 2011 |
Last Verified: | October 2006 |
Solifenacin tolterodine randomized controlled trial double-blind method |
Urinary Bladder, Overactive Urinary Bladder Diseases Urologic Diseases Lower Urinary Tract Symptoms Urological Manifestations Solifenacin Succinate Muscarinic Antagonists |
Cholinergic Antagonists Cholinergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Urological Agents |